Table 1 |.
Summary of trials involving single-agent HDAC inhibitors
| Agent | n | Lymphoma subtype | Outcomes | Common grade ≥3 adverse events (% of patients) | Year | Refs |
|---|---|---|---|---|---|---|
| Panobinostat | 35 | DLBCL | ORR 17.1% and CRR 11.4% | Thrombocytopenia (83); neutropenia (34); diarrhoea (11) | 2018 | 30 |
| Panobinostat | 139 | CTCL | ORR 17.3% | Thrombocytopenia (23); neutropenia (13); diarrhoea (6) | 2013 | 31 |
| Panobinostat | 129 | HL | ORR 27%, CRR 4% and median PFS 6.1 months | Thrombocytopenia (79); neutropenia (21); anaemia (21) | 2012 | 29 |
| Vorinostat | 56 | FL, NHL and MCL | FL: ORR 49% and median PFS 20 months; NHL: ORR 43%; MCL: ORR 0% | In 80% in total, including thrombocytopenia (48); neutropenia (41); leukopenia (12.5) | 2014 | 27 |
| Vorinostat | 35 | FL and MZL | FL: ORR 47% and CRR 23%; MZL: ORR 22% | Thrombocytopenia (29); neutropenia (17); lymphopenia (14) | 2011 | 28 |
| Abexinostat | 100 | NHL and CLL | ORR 28%; FL: ORR 56% | In 82% in total, including thrombocytopenia (80); neutropenia (27); anaemia (12) | 2017 | 32 |
| Mocetinostat | 72 | DLBCL and FL | DLBCL: ORR 18.9% and CBR 54.1%; FL: ORR 11.5% and CBR 73.1% | In 57% in total, including fatigue (23); neutropenia (15); thrombocytopenia (12) | 2017 | 34 |
| BeLinostat | 22 | Aggressive BCL | ORR 10.5% | Lymphopenia (10); all other adverse effects occurred in 5% or fewer patients | 2016 | 152 |
| Entinostat | 49 | HL | ORR 12%, CBR 24%, median PFS 5.5 months and OS 25.1 months | Thrombocytopenia (63); anaemia (47); neutropenia (41) | 2016 | 33 |
| Quisinostat | 26 | MF | ORR 24% and median PFS 5.1 months | Hypertension (4); fatigue (4); pruritus (4) | 2016 | 35 |
| Chidamide | 79 | PTCL | ORR 28%, CRR 14%, median PFS 2.1 months and median OS 21.4 months | Thrombocytopenia (22); leukopenia (13); neutropenia (11) | 2015 | 36 |
All trials included in this table were phase II designs. BCL, B cell lymphoma; CBR, clinical benefit rate; CLL, chronic lymphocytic leukaemia; CRR, complete response rate; CTCL, cutaneous T cell lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; HDAC, histone deacetylase; HL, Hodgkin lymphoma; MCL, mantle cell lymphoma; MF, mycosis fungoides and/or Sezary syndrome; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PTCL, peripheral T cell lymphoma.